Answers are grounded in this paper and cite their sources.
Using the SWITCHMRK and MONET trials as examples, Andrew Carr and colleagues question the ethics and motives of switch or simplification trials of anti-retroviral therapy.
No takes yet. Share an insight, caveat, or question.
Carr et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: